Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome by Juurmaa, Julius et al.
Brain and Behavior 2016; 6: e00539 wileyonlinelibrary.com/journal/brb3   |  1© 2016 The Authors. Brain and Behavior 
published by Wiley Periodicals, Inc.
Received: 15 January 2016  |  Revised: 29 June 2016  |  Accepted: 2 July 2016
DOI: 10.1002/brb3.539
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
Abstract
Background: A permanent Parkinsonian syndrome occurs in intravenous abusers of 
the designer psychostimulant methcathinone (ephedrone). It is attributed to deposi-
tion of contaminant manganese, as reflected by characteristic globus pallidus hyperin-
tensity on T1- weighted MRI.
Methods: We have investigated brain structure and function in methcathinone abus-
ers (n = 12) compared to matched control subjects (n = 12) using T1- weighted struc-
tural and resting- state functional MRI.
Results: Segmentation analysis revealed significant (p < .05) subcortical grey matter 
atrophy in methcathinone abusers within putamen and thalamus bilaterally, and the 
left caudate nucleus. The volume of the caudate nuclei correlated inversely with dura-
tion of methcathinone abuse. Voxel- based morphometry showed patients to have sig-
nificant grey matter loss (p < .05) bilaterally in the putamina and caudate nucleus. 
Surface- based analysis demonstrated nine clusters of cerebral cortical thinning in 
methcathinone abusers, with relative sparing of prefrontal, parieto- occipital, and tem-
poral regions. Resting- state functional MRI analysis showed increased functional con-
nectivity within the motor network of patients (p < .05), particularly within the right 
primary motor cortex.
Conclusion: Taken together, these results suggest that the manganese exposure asso-
ciated with prolonged methcathinone abuse results in widespread structural and func-
tional changes affecting both subcortical and cortical grey matter and their connections. 
Underlying the distinctive movement disorder caused by methcathinone abuse, there 
is a more widespread pattern of brain involvement than is evident from the hyperin-
tensity restricted to the basal ganglia as shown by T1- weighted structural MRI.
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1  | INTRODUCTION
Due to the ease of synthesis from readily available components meth-
cathinone (ephedrone) still presents a continuing public health hazard 
in many Eastern European countries. Intravenous abuse of this design-
er psychostimulant results in a levodopa- unresponsive Parkinsonian 
syndrome (Stepens et al., 2014). Home preparation of methcathinone 
by oxidation of the pseudoephedrine and ephedrine in common cold 
medications, in the presence of potassium permanganate, results in a 
high overload of manganese. The movement disorder closely resem-
bles that of chronic manganism, involving combinations of hypoki-
nesia, dysarthria, dystonia, and postural instability which manifest 
as facial impassivity, slowed movements, low volume speech, micro-
graphia, lurching gait with absent arm swing, and falls (Stepens et al., 
2008). This methcathinone/manganese- associated movement disor-
der can be severely disabling, is permanent, and shows no improve-
ment despite abstinence (Selikhova et al., 2008; Sikk et al., 2007; 
Stepens et al., 2008).
In active users of methcathinone, manganese blood levels are 
markedly elevated and associated with a distinctive T1- weighted MRI 
signal hyperintensity in the basal ganglia (Selikhova et al., 2008; Sikk 
et al., 2007; Stepens et al., 2008), which is attributable to manganese 
deposition (Klos et al., 2006). Diffusion- weighted MR tractography 
shows abusers to have diffuse white matter abnormalities throughout 
the brain, with severe focal damage in tracts underlying the right ven-
tral premotor cortex and the medial prefrontal cortex. These findings 
point to a widespread neuropathology underlying this disorder of high-
er level motor programming (Stepens et al., 2010). So far no studies 
have investigated grey matter pathology either within the basal ganglia 
or elsewhere in the brain. This MRI study investigates subcortical and 
cortical grey matter integrity in intravenous methcathinone abusers.
2  | METHODS
2.1 | Subject recruitment and clinical testing
Twelve intravenous drug abusers (mean age 32.4 years [range 22.4–
44.6]; eight men) who had self- reported using methcathinone for 
a mean period of 3.7 years (range 0.5–12), all showing the typical 
movement disorder, and 12 healthy age- and sex- matched controls 
(mean age 31.7 years [range 23.6–39.0]; eight men) underwent MRI. 
Abstinent users were defined by self- reported abstinence for ≥1 year, 
and by absence of globus pallidus hyperintensity on T1- weighted MRI. 
Informed consent was obtained in accordance with the Declaration 
of Helsinki and ethical approval was granted by the Research Ethics 
Committee of the University of Tartu and the Ethical Committee of 
Riga Stradins University.
Disability was quantified using the Movement Disorder Society- 
sponsored revision of the Unified Parkinson’s Disease Rating Scale 
(MDS- UPDRS; Goetz et al., 2008) which includes the Hoehn- Yahr 
(Hoehn & Yahr, 1967) and Schwab- England scales (Schwab & England, 
1969). Quality of life was assessed using the Parkinson’s Disease 
Quality of Life Questionnaire (PDQ- 39; Jenkinson, Fitzpatrick, Peto, 
Greenhall, & Hyman, 1997) and depressive symptoms were document-
ed using the Beck’s Depression Inventory (Beck, Ward, Mendelson, 
Mock, & Erbaugh, 1961). The Mini- mental State Examination (MMSE) 
was used to examine cognitive state (Folstein, Folstein, & McHugh, 
1975). Olfaction was tested using the Sniffin’ Sticks (SS- 12) smell 
test (Hummel, Konnerth, Rosenheim, & Kobal, 2001). Higher scores 
indicate more severe symptomatology on all clinical tests, except the 
Schwab- England scale and MMSE.
2.2 | Image acquisition
All MRI data were acquired using a MR scanner 3.0T Achieva (Philips 
Medical Systems) at Tartu University Hospital. Whole- brain T1- 
weighted scans were acquired using a 3D Fast Field Echo sequence 
with 146 axial slices (TR = 12 ms, TE = 3.2 ms, 1.0 mm isotropic 
resolution).
Resting- state fMRI data were acquired with dynamic T2*- weighted 
gradient echo single shot EPI- BOLD sequence (TR = 3,000 ms, 
TE = 35 ms, acquisition voxel size 3.0 mm isotropic). Sixty volumes 
were acquired with 47 axial slices.
2.3 | Image analysis
All image analysis was performed using tools from the FMRIB Software 
Library version 4.1 (FSL; Smith et al., 2004; www.fmrib.ox.ac.uk/fsl; 
RRID:SCR_002823) and FreeSurfer version 5.1 (Dale, Fischl, & Sereno, 
1999; surfer.nmr.mgh.harvard.edu; RRID:SCR_001847).
2.3.1 | Assessment of volume differences of 
subcortical grey matter structures
We segmented putamen, caudate, pallidum, and thalamus from each 
subject’s T1- weighted image using FMRIB’s Integrated Registration and 
Segmentation Tool (Patenaude, Smith, Kennedy, & Jenkinson, 2011). 
Furthermore, for each subject, brain tissue volume, normalized for sub-
ject head size, was estimated with SIENAX (Smith et al., 2002), part of 
FSL. SIENAX starts by extracting brain and skull images from the sin-
gle whole- head input data. The brain image is then affine registered 
to MNI152 space (using the skull image to determine the registration 
scaling); this is primarily in order to obtain the volumetric scaling factor, 
to be used for normalization for head size. Tissue- type segmentation 
with partial volume estimation is carried out in order to calculate total 
volume of brain tissue (including separate estimates of volumes of total 
grey matter, white matter, cortical grey matter, and ventricular CSF).
The results of each step of the image processing, most important-
ly the subcortical segmentation, were carefully examined to ensure 
accuracy of the results. As expected, the signal hyperintensities in the 
left and right pallidum prevented correct automated (as well as reliable 
manual) segmentation in the sub-group of patients who were active 
users; the pallidum was therefore excluded from volumetric analysis.
Before conducting statistical analyses, the volumes of each sub-
cortical region of interest were adjusted for inter individual head size 
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differences via multiplication by the volumetric scaling factor derived 
from SIENAX. All statistical analyses were carried out using IBM SPSS 
Statistics (Version 20). Statistical comparisons were carried out sepa-
rately for each hemisphere using independent samples t- tests. Pearson 
correlation coefficients were calculated to investigate the relationship 
between adjusted subcortical volumes and clinical rating scale scores.
2.3.2 | Voxel- based morphometry
T1- weighted MPRAGE data were analyzed using a standard approach 
with FSL voxel- based morphometry (VBM; part of FSL), a voxel- 
based morphometry style analysis (Ashburner & Friston, 2000; Good 
et al., 2001). First, structural images were brain extracted (Smith, 
2002). Next, tissue- type segmentation was carried out using FAST4 
(Zhang, Brady, & Smith, 2001). The resulting grey matter partial vol-
ume images were then aligned to MNI152 standard space using the 
affine registration tool FLIRT (Jenkinson, Bannister, Brady, & Smith, 
2002; Jenkinson & Smith, 2001), followed by nonlinear registration 
using FNIRT (Anderson, Andersson, Jenkinson, & Smith, 2007). The 
resulting images were averaged to create a study- specific template, 
to which the native grey matter images were then nonlinearly rereg-
istered. We then multiplied the registered partial volume images of 
all subjects by the Jacobian of the warp field (“modulation”) to cor-
rect for local expansion or contraction. The modulated segmented 
images were smoothed with an isotropic Gaussian kernel with a sigma 
of 3 mm.
To investigate group differences, a voxel- wise GLM was applied 
using permutation- based nonparametric testing with correction for 
multiple comparisons (family- wise error [FWE]; Smith & Nichols, 
2008).
2.3.3 | Cerebral cortical thickness analysis
Cortical reconstruction and volumetric segmentation were performed 
via a semiautomated process using the FreeSurfer image analysis 
suite. This processing includes removal of nonbrain tissue using a 
hybrid watershed/surface deformation procedure (Segonne, Pacheco, 
& Fischl, 2007), automated transformation to Talairach space, seg-
mentation of the subcortical white matter and deep grey matter 
volumetric structures (Fischl et al., 2002, 2004), intensity normaliza-
tion (Sled, Zijdenbos, & Evans, 1998), tessellation of the grey matter/
white matter boundary, automated topology correction (Fischl, Liu, & 
Dale, 2001; Segonne et al., 2007), and surface deformation following 
intensity gradients to demarcate the grey matter/white matter and 
grey matter/CSF borders at the location where the greatest shift in 
intensity defines the transition to the other tissue class (Dale et al., 
1999; Fischl & Dale, 2000). For two subjects, manual adjustment of 
watershed parameters for the skull stripping procedure was required; 
four subjects needed additional control points for complete tracing of 
brain tissue; and for one subject, tracing of the pial surface had to be 
corrected. Finally, completed cortical models were resampled into a 
common space (Fischl & Dale, 2000). Computations were carried out 
in the High Performance Computing Center of the University of Tartu.
Anatomical landmarks encompassed by clusters with statistically 
significant changes were labeled according to a complete parcellation 
of the cortical surface that uses internationally accepted standard 
nomenclature and criteria (Destrieux, Fischl, Dale, & Halgren, 2010). 
Graphical reconstructions were created using PySurfer.
Cortical thickness measurements by FreeSurfer have been exten-
sively validated against histological analysis (Rosas et al., 2002) and 
manual measurements (Kuperberg et al., 2003; Salat et al., 2004).
Cortical thickness was compared firstly between patients and con-
trols and then between active and abstinent users using mri_glmfit, 
part of the FreeSurfer toolkit. Inference was performed using per-
mutation testing and the maximum cluster size as the test statistic, 
allowing correction for multiple comparisons across surface vertices. A 
z- threshold corresponding to p < .05 was chosen for both the cluster- 
forming threshold and cluster- wise significance threshold.
2.3.4 | Resting- state functional MRI analysis
Resting- state fMRI analysis was carried out using the Multivariate 
Exploratory Linear Optimised Decomposition into Independent 
Components tool (Beckmann, DeLuca, Devlin, & Smith, 2005), part 
of FSL. First, standard preprocessing steps were performed on each 
individual subject’s fMRI images, consisting of motion correction, 
brain extraction, and spatial smoothing using a Gaussian kernel of 
full- width at half- maximum of 6 mm, and high- pass temporal filter-
ing equivalent to 150 s. Next, fMRI images were registered to the 
individual’s structural images using boundary- based linear registra-
tion and then to standard MNI space images using FNIRT (Anderson 
et al., 2007).
Preprocessed functional data containing 60 time points for each 
subject were temporally concatenated across subjects to create a 
single 4D dataset. Concatenated fMRI multiple datasets were decom-
posed using independent component analysis (ICA) to give 25 spatial 
components. Subsequently, components corresponding to the eight 
canonical resting- state networks (RSN) were selected (Beckmann 
et al., 2005). A dual- regression approach was used to identify, within 
each subject’s fMRI dataset, subject- specific temporal dynamics, and 
associated spatial maps. This involved spatial regression of group- ICA 
spatial maps against individual fMRI datasets, resulting in matrices 
describing temporal dynamics for each component and subject, fol-
lowed by temporal regression of time- course matrices against fMRI 
data to estimate subject- specific spatial maps. Finally, different com-
ponent maps (corresponding to a specific RSN) in each subject were 
concatenated into single 4D files.
To investigate group differences, a voxel- wise GLM was applied 
using permutation- based nonparametric testing, with FWE correc-
tion for multiple comparisons (Smith & Nichols, 2008). We specifically 
studied the motor network, using the default- mode network (DMN) 
as an anatomical control. The DMN is distinct from the motor network 
and there is no evidence of its involvement in this clinical syndrome.
In order to test for altered strength of functional coupling between 
the deep grey structures, functional connectivity was investigat-
ed based on regional correlations of the BOLD signal time courses. 
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The representative time course of activity for each structure (pall-
idum, putamen, caudate, and thalamus in MNI space) was extracted. 
Functional connectivity was calculated using Pearson correlation coef-
ficients between different structures, converted into Z statistics using 
Fisher’s r- to- Z transformation, and these resulting statistics were used 




Clinical rating scale results are summarized in Table 1. The patients’ 
MMSE scores demonstrated normal cognitive function and SS- 12 
scores indicated normal olfaction. MDS- UPDRS III (motor examina-
tion) subscores show patients had a significant impairment of motor 
function.
3.2 | Subcortical structure volume
Volume was significantly reduced in patients compared to controls for 
putamina and thalami bilaterally (right putamen: p = .036, left puta-
men: p = .019, right thalamus: p = .034, left thalamus: p = .015), and 
for the left caudate nucleus (p = .037).
The duration of methcathinone use correlated negatively with 
the volume of the right caudate nucleus (r = −.717, p = .009; Fig. 1A). 
Furthermore, there was a trend toward significant negative correlation 
between duration of methcathinone use and the volume of the left 
caudate nucleus (r = −.576, p = .05; Fig. 1B).
3.3 | Voxel- based morphometry
Whole- brain VBM analysis (excluding the globus pallidus) revealed 
areas of significant grey matter loss in patients compared to con-
trols in the left and right putamen and caudate, as well as in the deep 
left temporal lobe (Fig. 1C and D). No correlations with duration of 
methcathinone use were demonstrated.
3.4 | Cerebral cortical thickness
When compared to controls, patients displayed cortical thinning in a 
total of nine clusters (Fig. 2, Table 2). Notably, given the preserved 
MMSE scores, large areas of prefrontal, parietal, and temporal cortex 
were relatively spared.
Comparison of active (n = 5) and abstinent (n = 7) methcathinone 
users revealed less cortical thinning in active users in two clusters, 
comprising the postcentral gyrus and sulcus, superior parietal lobule, 
and the intraparietal sulcus and transverse parietal sulci of the left 
hemisphere (p = .016), and the central sulcus, postcentral gyrus, and 
sulcus, and the supramarginal gyrus in the right hemisphere (p = .023). 
There was no significant difference in the duration of methcathinone 
usage between active and abstinent users.
3.5 | Resting- state functional connectivity
We investigated functional connectivity within the motor network 
while the patients were at rest. Voxel- wise comparison revealed sev-
eral regions with significantly increased coactivation with the motor 
RSNs in patients compared to controls (p < .05), mainly within the 
right primary motor cortex (Fig. 3). No differences were seen in the 
control DMN.
There were no significant differences between patients and 
controls in functional connectivity between the basal ganglia struc-
tures (RM- ANOVA main effect of group [patients vs. controls; F(1, 
22) = 0.337, p = .567]).
4  | DISCUSSION
This is the first comprehensive study examining structural integrity and 
functional connectivity of cortical and subcortical grey matter struc-
tures in intravenous methcathinone abusers. Subcortical structure vol-
umetry and whole- brain voxel- based grey matter morphometry both 
showed significant striatal differences bilaterally between patients and 
controls. Furthermore, volumetric comparison revealed reduced tha-
lamic volume in methcathinone abusers. In addition to these changes 
affecting subcortical structures, surface- based analysis demonstrated 
widespread areas of cerebral cortical thinning in patients. Resting- state 
functional MRI analysis revealed significantly increased functional con-
nectivity at rest within the motor network in methcathinone abusers, 
particularly within the primary motor cortices bilaterally.
The observed pattern of subcortical grey matter loss is most 
likely to reflect the manganese toxicity associated with intravenous 
TABLE  1 Patients’ clinical rating scale results
Clinical test and component Scale Mean ± SE
MDS- UPDRS
I Nonmotor aspects of daily 
living
0–52 11.8 ± 3.5
II Motor aspects of daily 
living
0–52 15.5 ± 3.8
III Motor examination 0–132 35.8 ± 9.5
Total 0–236 63.0 ± 11.9
Hoehn- Yahr scale 0–5 3.5 ± 0.5
Schwab- England
 scale
0–100 65.0 ± 9.5
MMSE 0–30 28.9 ± 0.8
PDQ- 39
I Mobility 0–100 49.6 ± 16.6
II Activities of daily living 0–100 28.8 ± 10.8
III Emotional well- being 0–100 41.7 ± 11.9
IV Stigma 0–100 46.4 ± 15.6
V Social support 0–100 38.9 ± 12.3
VI Cognitive impairment 0–100 25.0 ± 13.0
VII Communication 0–100 51.4 ± 13.9
VIII Bodily discomfort 0–100 42.4 ± 11.3
Total 0–100 40.5 ± 6.5
SS- 12 0–12 9.4 ± 0.7
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methcathinone abuse. Neuropathological changes in manganese 
toxicity are mainly limited to basal ganglia structures; neurodegen-
eration and reactive changes have been observed in the globus 
pallidus, striatum, subthalamic nucleus, and substantia nigra pars 
reticulata (Aschner, Erikson, Herrero Hernandez, & Tjalkens, 2009). 
Damage to these basal ganglia structures is in keeping with the 
patients’ Parkinsonian clinical features. In particular, damage to the 
putamen, the most consistent site of grey matter loss in our study, 
is associated with motor symptomatology (Middleton & Strick, 
2000). Unfortunately, the MRI T1- weighted signal hyperintensity 
attributable to manganese deposition within the globi pallidi pre-
cluded reliable segmentation within the patient group, preventing 
assessment of morphometric group differences in this structure. 
Notably, our previous study of methcathinone abusers demonstrat-
ed increased mean diffusivity in the globus pallidus and a decrease 
in fractional anisotropy within globus pallidus–cortical connections 
(Stepens et al., 2010).
Functional coupling between brain regions, in part reflecting 
underlying anatomical connectivity, can be measured using resting- 
state functional connectivity. The cause of the increased functional 
F I G U R E  1 Negative correlation 
between duration of methcathinone abuse 
and caudate nucleus volume (A and B). 
Regions (caudate and putamen bilaterally) 
showing significant (pcorr < .05) grey 
matter atrophy in patients as compared 
with controls (C and D). y/z = MNI 
coordinates
F I G U R E  2 Clusters of significant 
cerebral cortical thinning in methcathinone 
abusers compared to controls. The color 
grading shows differing levels of statistical 
significance; highlighted areas all exceed 
the threshold of p < .05, corrected for 
multiple comparisons
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connectivity we demonstrated in the motor network remains unclear. 
This pattern of structural atrophy associated with increased function-
al connectivity has been described in a number of motor disorders, 
including Parkinson’s disease (Poston & Eidelberg, 2012) and amyo-
trophic lateral sclerosis (Douaud, Filippini, Knight, Talbot, & Turner, 
2011). This increase in functional connectivity in conjunction with 
structural atrophy may reflect either a compensatory adaptation 
response to injury, or a loss of inhibitory neuronal influences resulting 
from structural damage (Douaud et al., 2011).
Does methcathinone itself, in addition to the manganese toxic-
ity, contribute to the observed brain changes, as well as the clinical 
symptoms, of these patients? Animal models have shown that meth-
cathinone acts mainly on monoaminergic systems outside the extra-
pyramidal motor network (Gygi, Fleckenstein, Gibb, & Hanson, 1997; 
TABLE  2 Regions of reduced cortical thickness in patients compared with controls
Area, mm2 Landmarks Cluster- wise p
L 5,038 Superior frontal gyrus and sulcus 
Precentral gyrus and sulcus 
Paracentral lobule and sulcus 
Superior parietal lobule
.0002
L 5,711 Superior frontal sulcus 
Middle frontal gyrus and sulcus 
Fronto- marginal gyrus (of Wernicke) and sulcus 
Orbital gyrus and lateral orbital sulcus 
Inferior frontal gyrus and sulcus
.0002
L 3,199 Angular gyrus 
Supramarginal gyrus 
Posterior ramus of the lateral sulcus
.0002
L 1,298 Superior temporal sulcus 
Middle temporal gyrus 
Inferior temporal gyrus and sulcus
.0016
L 1,494 Precentral gyrus and sulcus 
Middle frontal gyrus
.0002
L 1,213 Lateral occipito- temporal gyrus and sulcus 
Medial occipito- temporal sulgus and lingual sulcus 
Inferior occipital gyrus and sulcus
.0030
L 1,409 Superior frontal gyrus 
Anterior and middle part of the cingulate gyrus and sulcus
.0022
R 11,357 Superior frontal gyrus and sulcus 
Middle frontal gyrus 
Inferior frontal gyrus and sulcus 
Fronto- marginal gyrus (of Wernicke) and sulcus 
Precentral gyrus and sulcus 
Paracentral gyrus and sulcus 
Marginal branch of the cingulate sulcus 
Middle part of the cingulate gyrus and sulcus
.0002
R 4,985 Superior parietal lobule 
Angular gyrus 
Anterior occipital sulcus 
Inferior occipital gyrus and sulcus 
Inferior temporal gyrus and sulcus 
Lateral occipito- temporal gyrus and sulcus
.0002
F I G U R E  3 Group differences in the 
motor resting- state networks between 
patients and controls. Red- yellow regions 
indicate voxels showing a significant 
increase in functional connectivity in 
patients compared with controls. Color bar 
indicates p- values, corrected for multiple 
comparisons. x/y/z = MNI coordinates
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Gygi, Gibb, & Hanson, 1996). Human imaging studies showed normal 
dopamine levels and intact presynaptic nigrostriatal neurons in cases 
of methcathinone/manganese- induced movement disorder (Sikk et al., 
2010); suggesting manganese rather than methcathinone as the main 
causative agent of movement disorder in our patients. Methcathinone 
is an “amphetamine- like” drug and methcathinone and amphetamine 
have similar chemical structures (Glennon, Yousif, Naiman, & Kalix, 
1987). The most consistently observed change associated with chron-
ic amphetamine abuse is reduced cerebral cortical grey matter density 
and volume, along with enlargement of the globus pallidus and putamen 
(Berman, O’Neill, Fears, Bartzokis, & London, 2008). It seems that the 
structural changes caused by chronic amphetamine abuse mainly affect 
the cortex, whereas manganese toxicity predominantly produces sub-
cortical damage. It may be, therefore, that intravenous methcathinone 
abuse is a “double toxin” with manganese toxicity affecting the sub-
cortical structures and the methcathinone component leading to the 
widespread changes in cerebral cortical thickness. It is worth noting, 
however, that a similar pattern of widespread cortical thinning has been 
seen in progressive supranuclear palsy (Worker et al., 2014), a disease 
that shares many clinical features with those seen in our cohort of meth-
cathinone abusers. This finding would suggest that the cortical thinning 
observed in our patients may be a result of neurodegeneration second-
ary to the subcortical damage caused by manganese toxicity rather than 
the direct effect of methcathinone per se, although a histopathological 
study would be required to confirm or refute these hypotheses.
5  | CONCLUSION
We have demonstrated widespread atrophy and increased func-
tional connectivity within the brains of methcathinone abusers 
with a manganese- induced movement disorder. These abnormali-
ties occurred both within and outside the basal ganglia. The damage 
localized to subcortical structures within the motor loop of the basal 
ganglia is likely to be attributable to manganese toxicity and probably 
underlies the distinctive nature of this stereotyped motor syndrome. 
This notion is supported by the resting- state fMRI analysis revealing 
increased functional connectivity within the motor network. Our iden-
tification of diffuse cerebral cortical thinning may reflect an additional 
toxic effect of methcathinone, by analogy with the effects of ampheta-
mine, a similar stimulant. Overall our results illustrate that in intrave-
nous methcathinone/manganese abusers there is a more widespread 
pattern of grey matter damage than demonstrable by conventional 
imaging techniques.
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